Insider buying last 90 days
No open-market insider purchases were filed for VCYT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VCYT insider filing, plotted on the chart in Gekko.Open VCYT in Gekko
NASDAQ: VCYT
Veracyte (VCYT) Stock Analysis & Forecast
Oct 12 close
$44.02−1.21 (−2.7%)
Gekko Brief
AI summaryOct 12 closeVeracyte this week drew attention from analyst activity and valuation commentary. Argus lowered its target price on the stock, while separate coverage of its financial ratios highlighted a market cap of $3,636 Mln and a P/E ratio of 32.3. Another piece flagged a GF Value of $39.27 against a recent price of $47.67, questioning valuation and noting insider selling without offsetting buying.
VCYT closed at $44.02, down 2.7%, but remains above both its 50-day average of $43.72 and 200-day average of $42.57, with the 50-day above the 200-day. The GekkoIndex reads 58.6, placing the stock in the Neutral zone. Gekko Fair Value stands at $46.66, putting the current price 5.7% below that level.
Over the next 20 trading days, the main event is the earnings report due 3 November 2026, after the close, which falls inside that window; the prior report produced a 16.9% reaction despite beating estimates. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows. Seasonally, the stock has averaged a 23.4% move over the next 20 trading days across 5 years, rising in all 5 of them, a pattern worth noting alongside the earnings timing.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Veracyte price vs fair value
Close $44.02200-day averageGekko Fair Value $46.66
Veracyte quick facts
- Market cap
- $3.51B
- P/E ratio
- 31.1
- Forward P/E
- 23.6
- EPS, TTM
- $1.40
- Revenue, TTM
- $561.9M
- Profit margin
- 20.4%
- Dividend yield
- —
- Beta
- 1.95
- Volume
- 1.15M avg 1.55M
- 1-year return
- +26.0%
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±9.6%
- 50-day average
- $43.72
- 200-day average
- $42.57
- Next earnings
- Nov 3 after close
- Shares outstanding
- 80.39M
Veracyte swing-trade checklist
Veracyte scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $44.02 is above the 50-day ($43.72) and 200-day ($42.57) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
58.6, Neutral
Reading 58.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
5.7% below
Price is 5.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+23.4% on average
From this point in the calendar, the next 20 trading days averaged +23.4% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Veracyte stock chart and price history
Veracyte closed at $44.02 on Oct 12, 2026, +26.0% over the past year, inside a 52-week range of $29.46 to $60.91.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.7%
- 3 months
- −22.3%
- 6 months
- +35.7%
- 1 year
- +26.0%
The full VCYT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VCYT in Gekko
Follow Veracyte through every session
Put VCYT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VCYT in GekkoFree for 7 days. No credit card required.
About Veracyte
Veracyte develops diagnostic tests used to help identify and classify several forms of cancer. Its offerings include a genomic test for assessing thyroid nodules, classifiers used in diagnosing prostate and bladder cancer, a breast cancer assay, and a nasal swab test aimed at lung cancer detection. These products position the company around genomic analysis tools that support cancer-related clinical decisions.
Beyond its diagnostic panels, Veracyte also supplies services tied to the nCounter analysis system, broadening its offering beyond standalone tests. The company serves patients and clinicians both within the United States and in markets abroad, applying its genomic classifiers across a range of cancer types rather than focusing on a single disease area.
Veracyte was incorporated in 2006 and operated for a time under the name Calderome, Inc. before adopting its current name in March 2008. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ under the ticker VCYT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- veracyte.com
Veracyte GekkoIndex: the smart money zone
Veracyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.6, in the Neutral zone, up 3.8 points over five sessions.
58.6Neutral
Up 3.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +1.7% | +1.6% | ||
| Accumulation | 249 | −0.3% | −1.4% | ||
| Neutral (current zone) | 351 | +1.3% | +4.7% | ||
| Distribution | 47 | +0.1% | +9.5% | ||
| Selling | 1 | Too few readings yet | |||
Average VCYT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the VCYT price, zone by zone.Track VCYT in Gekko
Is Veracyte stock overvalued? Gekko Fair Value
Veracyte trades 5.7% below Gekko Fair Value of $46.66, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Veracyte shares are worth, recalculated every trading day.
$46.66
Gekko Fair Value, Oct 10, 2026
5.7% Undervalued
At the end of Aug 2026 the price was 11.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VCYT in Gekko
Veracyte insider and Congress trading
No open-market insider purchases were filed for Veracyte, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VCYT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VCYT, plotted on the chart in Gekko.Open VCYT in Gekko
Buybacks
Veracyte has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $4.29M
- As a share of market cap
- 0.12%
From company filings.
Veracyte earnings: next date and track record
Veracyte reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- $0.41
- Revenue estimate
- $147.2M
8 of 8reports beat the EPS estimate
±13.3%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | $0.54 est $0.41 | $150.3M est $144.6M | −16.9% |
| May 5, 2026 | $0.52 est $0.33 | $139.1M est $130.4M | +23.1% |
| Feb 25, 2026 | $0.53 est $0.41 | $140.6M est $135.8M | +8.6% |
| Nov 4, 2025 | $0.51 est $0.32 | $131.9M est $135.8M | +26.3% |
| Aug 6, 2025 | $0.44 est $0.31 | $130.2M est $124.4M | +10.7% |
| May 7, 2025 | $0.31 est $0.20 | $114.5M est $111.0M | +2.1% |
| Feb 24, 2025 | $0.36 est $0.26 | $118.6M est $110.7M | −14.6% |
| Nov 6, 2024 | $0.19 est $0.03 | $115.9M est $116.7M | +3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Veracyte stock forecast and analyst price targets
Analysts’ average 12-month price target for Veracyte is $58.42, +32.7% from the last close, from 10 firms rating the stock in the last 90 days.
$58.42consensus 12-month target, +32.7% from the last close
Now $44.02Avg $58.42
Low $44High $69
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Piper Sandler | $54 | +22.7% |
| Sep 15 | Needham | $69 | +56.7% |
| Sep 15 | William Blair | — | — |
| Sep 15 | Craig-Hallum | — | — |
| Sep 15 | Freedom Capital Markets | $66 | +49.9% |
+4.7%average 20-day move after past Neutral readings
+23.4%average move over the next 20 trading days in the last 5 years
±6.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Veracyte seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Veracyte averaged +23.4% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.0% | 4 of 5 |
| Next 10 trading days | +2.5% | 3 of 5 |
| Next 15 trading days | +11.0% | 4 of 5 |
| Next 20 trading days | +23.4% | 5 of 5 |
| Next 30 trading days | +26.1% | 5 of 5 |
For scale, VCYT’s typical 20-trading-day move in either direction is about 9.6%.
Veracyte market cap and key statistics
Veracyte’s market cap is $3.51B, with a P/E ratio of 31.1 and revenue of $561.9M over the last twelve months.
Valuation
- Market cap
- $3.51B
- P/E ratio
- 31.1
- Forward P/E
- 23.6
- EPS, TTM
- $1.40
- Gekko Fair Value
- $46.66
Trading
- Volume
- 1.15M
- Avg volume, 20 days
- 1.55M
- 52-week high
- $60.91
- 52-week low
- $29.46
- Shares outstanding
- 80.39M
Financials
- Revenue, TTM
- $561.9M
- Profit margin
- 20.4%
- Return on equity
- 8.8%
- Quarterly earnings growth, YoY
- +288.9%
Risk and income
- Beta
- 1.95
- Typical daily move
- ±6.3%
- Typical 20-day move
- ±9.6%
Veracyte stock news this week
Coverage of Veracyte this week reads neutral: 1 positive, 1 neutral and 1 negative headlines.
- Veracyte, Inc. (VCYT) Stock ForecastsYahoo! Finance Canada, Oct 10
- Veracyte Inc. (VCYT) Key Financial Ratios – Valuation, Profitability & MoreValue Research, Oct 9
- A Look at Veracyte Inc (VCYT) After 4.1% Gain -- GF Value $39.27 vs Price $47.67GuruFocus, Oct 6
Veracyte peers
Veracyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Veracyte stock FAQ
What is Veracyte’s market cap?
Veracyte’s market cap is $3.51B at the Oct 12, 2026 close of $44.02, with 80.39M shares outstanding. The shares trade on a P/E ratio of 31.1.
What is the Veracyte stock forecast?
The consensus analyst 12-month price target for Veracyte is $58.42, +32.7% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Veracyte stock overvalued or undervalued?
On Gekko’s estimate Veracyte is undervalued: the Oct 12, 2026 close of $44.02 is 5.7% below Gekko Fair Value of $46.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Veracyte report earnings next?
Veracyte is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of $0.41 per share on revenue of $147.2M. Veracyte beat the earnings estimate in 8 of its last 8 reports, moving 13.3% on average across the report.
What is Veracyte’s 52-week high and low?
Veracyte’s 52-week high is $60.91 and its 52-week low is $29.46; it closed at $44.02 on Oct 12, 2026, +26.0% over the past year.
Is Veracyte stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Veracyte the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.